Towa Pharmaceutical Profit Slumps but Dividend Rises as Company Forecasts Strong Rebound

Towa Pharmaceutical Co ( (JP:4553) ) has shared an announcement.

Towa Pharmaceutical reported consolidated net sales of ¥273.7 billion for the year ended March 31, 2026, up 5.4% year on year, while operating profit was roughly flat at ¥23.1 billion and ordinary profit rose 7.4%. Profit attributable to owners of parent, however, dropped 72.3% to ¥5.25 billion, sharply reducing earnings per share, even as total assets and equity both inched higher and the equity ratio improved to 37.5%.

Despite the earnings slump, the company raised its annual dividend to ¥80 per share, implying a substantially higher payout ratio, and plans a further increase to ¥85 in the current fiscal year. For the year ending March 31, 2027, Towa forecasts double-digit growth in sales to ¥304 billion and a more than threefold rebound in bottom-line profit to ¥21.5 billion, signaling management’s confidence in a profit recovery and a stronger earnings base for shareholders.

The most recent analyst rating on (JP:4553) stock is a Buy with a Yen3500.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.

More about Towa Pharmaceutical Co

Towa Pharmaceutical Co., Ltd. is a Japan-based drug maker listed on the Tokyo Stock Exchange, operating in the pharmaceutical industry with a focus on prescription medicines. The company generates revenue primarily from generic and other pharmaceutical products, serving domestic and overseas healthcare markets and institutional customers.

Average Trading Volume: 122,324

Technical Sentiment Signal: Buy

Current Market Cap: Yen159.7B

See more data about 4553 stock on TipRanks’ Stock Analysis page.